Hip Fracture Risk in Patients with a Diagnosis of Pernicious Anemia

Overview

Journal Gastroenterology

Specialty Gastroenterology

Date 2009 Dec 23

PMID 20026065

Citations 19

Authors

Nathan A Merriman

Mary E Putt

David C Metz

Yu-Xiao Yang

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Pernicious anemia (PA) is characterized by vitamin B-12 deficiency and achlorhydria, both of which have a detrimental effect on bone strength. The principle aim of this study was to determine the risk of hip fracture in patients with PA.

Methods: This is a retrospective cohort study using the General Practice Research Database (GPRD) from the United Kingdom. GPRD data from May 1987 until April 2002 were utilized to identify patients between 40 and 90 years of age at the time of GPRD enrollment. The exposed group contained patients with a diagnosis of PA being treated with vitamin B-12 therapy. We matched each patient having a diagnosis of PA with 4 randomly selected non-PA patients with respect to age (+/-1 year) and sex. Cox regression analysis was used to determine the hazard ratio (HR) for hip fracture associated with PA.

Results: Nine thousand five hundred six patients with a diagnosis of PA receiving vitamin B-12 injection therapy were identified and compared to 38,024 controls. Patients with PA had a greater risk of hip fracture than the controls (HR = 1.74; 95% CI: 1.45-2.08). The increase in hip fracture risk was even more pronounced among those patients newly diagnosed with PA during GPRD follow-up (HR = 2.63; 95% CI: 2.03-3.41).

Conclusions: Patients with a diagnosis of PA have an elevated risk of hip fracture. The increased hip fracture risk was persistent even years after vitamin B-12 therapy. Chronic achlorhydria could be the mechanism contributing to the persistently elevated hip fracture risk.

Citing Articles

Osteoblast Lineage Support of Hematopoiesis in Health and Disease.

Kim M, Valderrabano R, Wu J J Bone Miner Res. 2022; 37(10):1823-1842.

PMID: 35983701 PMC: 11346465. DOI: 10.1002/jbmr.4678.

Vitamin B12 reduces the negative effects of nicotine on fetal bone development in the rats.

Payas A, Ekinci Y, Gurbuz K, Batin S, Ertekin T, Dogan K Jt Dis Relat Surg. 2022; 33(1):216-224.

PMID: 35361098 PMC: 9057541. DOI: 10.52312/jdrs.2022.552.

Anaemia Is Associated with an Increased Risk of Fractures, a Systematic Review, and Meta-Analysis.

Tari E, Vorhendi N, Kiss S, Teutsch B, Varadi A, Sisak K Gerontology. 2022; 69(1):1-13.

PMID: 35314584 PMC: 9808740. DOI: 10.1159/000522591.

Bone Fragility in Gastrointestinal Disorders.

Merlotti D, Mingiano C, Valenti R, Cavati G, Calabrese M, Pirrotta F Int J Mol Sci. 2022; 23(5).

PMID: 35269854 PMC: 8910640. DOI: 10.3390/ijms23052713.

Maternal vitamin B in mice positively regulates bone, but not muscle mass and strength in post-weaning and mature offspring.

Singh P, Telnova S, Zhou B, Mohamed A, de Mello V, Wackerhage H Am J Physiol Regul Integr Comp Physiol. 2021; 320(6):R984-R993.

PMID: 33759575 PMC: 8285619. DOI: 10.1152/ajpregu.00355.2020.

References

Tucker K, Hannan M, Qiao N, Jacques P, Selhub J, Cupples L . Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res. 2004; 20(1):152-8. DOI: 10.1359/JBMR.041018. View

Kim G, Kim C, Park J, Lee K, Park C . Effects of vitamin B12 on cell proliferation and cellular alkaline phosphatase activity in human bone marrow stromal osteoprogenitor cells and UMR106 osteoblastic cells. Metabolism. 1996; 45(12):1443-6. DOI: 10.1016/s0026-0495(96)90171-7. View

Kaye J, Jick H . Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008; 28(8):951-9. DOI: 10.1592/phco.28.8.951. View

Eastell R, Vieira N, Yergey A, Wahner H, SILVERSTEIN M, Kumar R . Pernicious anaemia as a risk factor for osteoporosis. Clin Sci (Lond). 1992; 82(6):681-5. DOI: 10.1042/cs0820681. View

Mizunashi K, Furukawa Y, Katano K, Abe K . Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993; 53(1):21-5. DOI: 10.1007/BF01352010. View

Saltzman J, Kemp J, Golner B, Pedrosa M, Dallal G, Russell R . Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr. 1994; 13(6):584-91. DOI: 10.1080/07315724.1994.10718452. View

Marcuard S, Albernaz L, Khazanie P . Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994; 120(3):211-5. DOI: 10.7326/0003-4819-120-3-199402010-00006. View

Chonan O, Takahashi R, Yasui H, Watanuki M . Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo). 1998; 44(3):473-81. DOI: 10.3177/jnsv.44.473. View

Carmel R, Lau K, Baylink D, Saxena S, Singer F . Cobalamin and osteoblast-specific proteins. N Engl J Med. 1988; 319(2):70-5. DOI: 10.1056/NEJM198807143190202. View

10.

Walley T, Mantgani A . The UK General Practice Research Database. Lancet. 1999; 350(9084):1097-9. DOI: 10.1016/S0140-6736(97)04248-7. View

11.

OConnell M, Madden D, Murray A, Heaney R, Kerzner L . Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005; 118(7):778-81. DOI: 10.1016/j.amjmed.2005.02.007. View

12.

Garcia Rodriguez L, Perez Gutthann S . Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998; 45(5):419-25. PMC: 1873548. DOI: 10.1046/j.1365-2125.1998.00701.x. View

13.

van Staa T, Wegman S, de Vries F, Leufkens B, Cooper C . Use of statins and risk of fractures. JAMA. 2001; 285(14):1850-5. DOI: 10.1001/jama.285.14.1850. View

14.

Vestergaard P, Rejnmark L, Mosekilde L . Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006; 79(2):76-83. DOI: 10.1007/s00223-006-0021-7. View

15.

Grimelius L, Johansson H, Lundqvist G, Olazabal A, Polak J, Pearse G . The parathyroid glands in experimentally induced hypergastrinemia in the rat. Scand J Gastroenterol. 1977; 12(6):739-44. DOI: 10.3109/00365527709181713. View

16.

Chisholm J . The Read clinical classification. BMJ. 1990; 300(6732):1092. PMC: 1662793. DOI: 10.1136/bmj.300.6732.1092. View

17.

Goerss J, Kim C, Atkinson E, Eastell R, OFallon W, Melton 3rd L . Risk of fractures in patients with pernicious anemia. J Bone Miner Res. 1992; 7(5):573-9. DOI: 10.1002/jbmr.5650070514. View

18.

Graziani G, Badalamenti S, Como G, Gallieni M, Finazzi S, Angelini C . Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron. 2002; 91(3):474-9. DOI: 10.1159/000064290. View

19.

De Geronimo S, Romagnoli E, Diacinti D, DErasmo E, Minisola S . The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol. 2006; 155(3):415-20. DOI: 10.1530/eje.1.02225. View

20.

Yang Y, Lewis J, Epstein S, Metz D . Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296(24):2947-53. DOI: 10.1001/jama.296.24.2947. View